ProCE Banner Activity

Selecting Therapy for Patients With Advanced Systemic Mastocytosis

Clinical Thought
Despite the rarity of systemic mastocytosis, multiple therapies are available to manage advanced disease. In this commentary, I review key data on current treatment options and how I individualize therapy for patients with advanced systemic mastocytosis.

Released: April 21, 2022

Expiration: April 20, 2023

No longer available for credit.

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Blueprint Medicines

Faculty Disclosure

Primary Author

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has received consulting fees from AbbVie, Blueprint Medicines, Bristol-Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, Pharma Essentia, and Sierra Oncology and funds for research support from Astellas, Blueprint Medicines, Bristol-Myers Squibb, Cogent, Constellation, CTI BioPharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.